A novel DNA methylation signature is associated with androgen receptor activity and patient prognosis in bone metastatic prostate cancer

Table 1 Clinical characteristics of patients with prostate cancer from whom samples of bone metastases were analyzed by Infinium Methylation EPIC arrays

Clinical characteristics	Hormone-naíve n = 14	Short-term castrated^a n = 4	Castration-resistant^b n = 52
Age at diagnosis (years)	78 (74–80)	75 (72–76)	71 (64–75)
Age at metastasis surgery (years)	–	–	73 (68–80)
Serum PSA at diagnosis (ng/ml)	320 (82–980)	2300 (560–4300)	82 (40–510)
Serum PSA at metastasis surgery (ng/ml)	–	–	250 (82–630)
Bicalutamide prior to metastasis surgery^c
Yes	0	0	28
No	14	4	24
Radiation prior to metastasis surgery^d
Yes	0	0	7
No	14	4	45
Chemotherapy prior to metastasis surgery
Yes	0	0	9
No	14	4	43
Ra-223 prior to metastasis surgery
Yes	0	0	6
No	14	4	46

Continuous values are given as median (25th; 75th percentiles)
^aShort-term treated patients had received androgen ablation therapy for 1–3 days before metastasis surgery
^bCastration-resistant patients had disease progression after long-term androgen deprivation therapy. First line androgen-deprivation therapy (ADT) includes surgical ablation, LHRH/GNRH agonist therapy, and therapy with anti-androgens
^cCastration therapy as stated above and bicalutamide for treatment of CRPC
^dRadiation towards operation site

ISSN: 1868-7083